The Glaucoma Laser Trial (GLT): 3. Design and methods |
| |
| Affiliation: | 1. Department of Ophthalmology and Visual Sciences, Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan;2. Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India;3. Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;4. Institute of Social Research, University of Michigan, Ann Arbor, Michigan;5. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan;6. Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan;7. Department of Ophthalmology, Johns Hopkins University, Baltimore, Maryland;8. Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland;1. Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan;2. Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan;1. Channing Division of Network Medicine, Department of Medicine, Harvard Medical School and Brigham & Women''s Hospital, Boston, Massachusetts;2. Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts |
| |
| Abstract: | The Glaucoma Laser Trial (GLT) was an investigator-initiated, grant-supported, multicenter, randomized, controlled clinical trial designed to investigate the efficacy and safety of argon laser trabeculoplasty (ALT) as an alternative to medical treatment for newly diagnosed primary open-angle glaucoma (POAG). One eye of each patient was randomly assigned to ALT followed by medical treatment if needed to control intraocular pressure (IOP). The patient's other eye was assigned to medical treatment. Medical treatment for either eye was prescribed according to a stepped sequence. Patients were followed for a minimum of 2 years. Monitoring for control of IOP and for adherence to the protocol continued throughout the followup period. This article describes the design and methods of the trial and provides a discussion of the underlying rationale for key design decisions. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
